Literature DB >> 30651281

Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy.

Daniel J Landsburg1, Mitchell E Hughes2, Alexa Koike3, David Bond4, Kami J Maddocks4, Ling Guo5, Allison M Winter6, Brian T Hill6, Sarah L Ondrejka7, Eric D Hsi7, Sunita D Nasta1, Jakub Svoboda1, Stephen J Schuster1, Agata M Bogusz3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30651281      PMCID： PMC6341198          DOI： 10.1182/bloodadvances.2018026401

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  14 in total

1.  Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Authors:  Tina Marie Green; Ken H Young; Carlo Visco; Zijun Y Xu-Monette; Attilio Orazi; Ronald S Go; Ole Nielsen; Ole V Gadeberg; Torben Mourits-Andersen; Mikael Frederiksen; Lars Møller Pedersen; Michael Boe Møller
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

2.  Evaluation of intra- and interobserver agreement and its clinical significance for scoring bcl-2 immunohistochemical expression in diffuse large B-cell lymphoma.

Authors:  Vinicius Freitas Borlot; Irene Biasoli; Rony Schaffel; Denize Azambuja; Cristiane Milito; Ronir Raggio Luiz; Adriana Scheliga; Nelson Spector; José Carlos Morais
Journal:  Pathol Int       Date:  2008-09       Impact factor: 2.534

3.  A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib.

Authors:  Allison M Winter; Daniel J Landsburg; Anthony R Mato; Krista Isaac; Francisco J Hernandez-Ilizaliturri; Nishitha Reddy; Stephen Smith; Mazyar Shadman; Mitchell R Smith; Paolo Caimi; Deepa Jagadeesh; Brian T Hill
Journal:  Blood       Date:  2017-10-05       Impact factor: 22.113

4.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

Review 5.  The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Authors:  Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

6.  MYC Protein-positive Diffuse Large B-Cell Lymphoma Features an Activated B-Cell Receptor Signal Pathway.

Authors:  Wei-Ge Wang; Xiang-Nan Jiang; Ze-Bing Liu; Xiao-Yan Zhou; Xiao-Qiu Li
Journal:  Am J Surg Pathol       Date:  2017-04       Impact factor: 6.394

7.  Comparison of evaluation techniques, including digital image analysis, for MYC protein expression by immunohistochemical stain in aggressive B-cell lymphomas.

Authors:  Meghan Hupp; Sarah Williams; Brian Dunnette; Katelyn M Tessier; Elizabeth L Courville
Journal:  Hum Pathol       Date:  2018-08-30       Impact factor: 3.466

8.  Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.

Authors:  Wyndham H Wilson; Ryan M Young; Roland Schmitz; Yandan Yang; Stefania Pittaluga; George Wright; Chih-Jian Lih; P Mickey Williams; Arthur L Shaffer; John Gerecitano; Sven de Vos; Andre Goy; Vaishalee P Kenkre; Paul M Barr; Kristie A Blum; Andrei Shustov; Ranjana Advani; Nathan H Fowler; Julie M Vose; Rebecca L Elstrom; Thomas M Habermann; Jacqueline C Barrientos; Jesse McGreivy; Maria Fardis; Betty Y Chang; Fong Clow; Brian Munneke; Davina Moussa; Darrin M Beaupre; Louis M Staudt
Journal:  Nat Med       Date:  2015-07-20       Impact factor: 53.440

9.  Quantitative immunofluorescence reveals the signature of active B-cell receptor signaling in diffuse large B-cell lymphoma.

Authors:  Agata M Bogusz; Richard H G Baxter; Treeve Currie; Papiya Sinha; Aliyah R Sohani; Jeffery L Kutok; Scott J Rodig
Journal:  Clin Cancer Res       Date:  2012-09-10       Impact factor: 12.531

10.  Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Authors:  Nathalie A Johnson; Graham W Slack; Kerry J Savage; Joseph M Connors; Susana Ben-Neriah; Sanja Rogic; David W Scott; King L Tan; Christian Steidl; Laurie H Sehn; Wing C Chan; Javeed Iqbal; Paul N Meyer; Georg Lenz; George Wright; Lisa M Rimsza; Carlo Valentino; Patrick Brunhoeber; Thomas M Grogan; Rita M Braziel; James R Cook; Raymond R Tubbs; Dennis D Weisenburger; Elias Campo; Andreas Rosenwald; German Ott; Jan Delabie; Christina Holcroft; Elaine S Jaffe; Louis M Staudt; Randy D Gascoyne
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544
View more
  4 in total

Review 1.  Cellular Immunotherapy for Refractory Diffuse Large B Cell Lymphoma in the Chimeric Antigen Receptor-Engineered T Cell Era: Still a Role for Allogeneic Transplantation?

Authors:  Peter Dreger; Timothy S Fenske; Silvia Montoto; Marcelo C Pasquini; Anna Sureda; Mehdi Hamadani
Journal:  Biol Blood Marrow Transplant       Date:  2020-01-07       Impact factor: 5.742

2.  Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience.

Authors:  Yu-Wen Wang; Xavier Cheng-Hong Tsai; Hsin-An Hou; Feng-Ming Tien; Jia-Hau Liu; Wen-Chien Chou; Bor-Sheng Ko; Yu-Wen Chen; Chien-Chin Lin; Chieh-Lung Cheng; Min-Yen Lo; Yun-Chu Lin; Li-Chun Lu; Shang-Ju Wu; Sung-Hsin Kuo; Ruey-Long Hong; Tai-Chung Huang; Ming Yao
Journal:  Ann Hematol       Date:  2021-11-11       Impact factor: 3.673

Review 3.  Molecular Diagnostic Review of Diffuse Large B-Cell Lymphoma and Its Tumor Microenvironment.

Authors:  Robert Ta; David Yang; Christian Hirt; Thomas Drago; Richard Flavin
Journal:  Diagnostics (Basel)       Date:  2022-04-27

4.  Cooperative miRNA-dependent PTEN regulation drives resistance to BTK inhibition in B-cell lymphoid malignancies.

Authors:  Isha Kapoor; Juraj Bodo; Brian T Hill; Alexandru Almasan
Journal:  Cell Death Dis       Date:  2021-11-08       Impact factor: 8.469
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.